Antaros Medical, in collaboration with Sanofi, presents important data at the 53rd Annual Meeting of the European Association for the study of diabetes (EASD) on a first-in-class Glucagon (GCG) Positron Emission Tomography (PET) ligand, with suitable properties for clinical development targeting the glucagon receptor.
- First-in-class PET tracerfor the glucagon receptor
Eriksson O, Bossart M, Haack T, Laitinen I, Larsen P,Plettenburg O, Johansson L, Pierrou S, Wagner M, Velikyan I.
In addition, Antaros founders contribute to science at EASD 2017 in three additional poster:
- CDKN2C expression is low in type 2 diabetes and associated with reduced lipid storage capacity in subcutaneous adipose tissue and elevated free fatty acid levels
Pereira MJ, Skrtic A, Katsogiannos P, Abrahamsson N, Kullberg J, Nowak C, Eriksson JW
- Glucose uptake in skeletal muscle, brain and VAT glucose uptake assessed with PET/MR together strongly predict whole body glucose uptake during hyperinsulinemia
Boersma GJ, Heurling K, Pereira MJ, Johansson E, Lubberink M, Börjesson JL, Katsogiannos P, Skrtic S, Kullberg J, Ahlström H, Eriksson JW
- Effects of the SGLT2 inhibitor dapagliflozin on tissue specific insulin sensitivity and liver fat content in type 2 diabetes patients: a randomised placebo controlled study
Hyypia A, Makine J, Oscarsson J, Hannukainen J, Kullberg J, Johansson L, Nuutila P, Miikka-Juhani Honka MJ